This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ramanuja, S. Articles by Kalaria, V. G. Search for Related Content PubMed PubMed Citation Articles by Ramanuja, S. Articles by Kalaria, V. G. Related Collections Cardiovascular Pharmacology Platelets Related Article

(Circulation. 2004;110:e1-e4.)
© 2004 American Heart Association, Inc.

Clinician Update

Approach to "Aspirin Allergy" in Cardiovascular Patients

Srinivasan Ramanuja, MD; Jeffrey A. Breall, MD, PhD; Vijay G. Kalaria, MD

From the Krannert Institute of Cardiology, Clarian Cardiovascular Center, Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind.

Correspondence to Vijay G. Kalaria, MD, FACC, FSCAI, Associate Director, Catheterization Laboratories and Interventional Cardiology, Krannert Institute of Cardiology, Indiana University School of Medicine, Clarian Cardiovascular Center, E404, 1800 North Capitol Ave, Indianapolis, IN 46202. E-mail vkalaria@iupui.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Aspirin (ASA), by irreversibly inhibiting platelet cyclooxygenase-1 enzyme (COX-1), prevents platelet aggregation and is the mainstay of pharmacotherapy of patients with coronary artery disease (CAD). Long-term ASA therapy reduces mortality in CAD patients after an initial coronary event. Periprocedural ASA therapy significantly reduces major adverse cardiovascular events (MACE) after percutaneous coronary interventions.^1,2 Despite a plethora of clinical data showing marked efficacy of ASA therapy in cardiovascular patients, ASA use continues to be less than optimal in real-world registries.^3,4 A history of adverse reactions to ASA may prevent long-term use in a cardiovascular patient, thereby reducing optimal event protection. Most adverse reactions to ASA, such as gastrointestinal intolerance, are predictable and are dose and host related.⁵ However, ASA can also cause a hypersensitivity reaction, of which there are 3 types: respiratory sensitivity (asthma and/or rhinitis), cutaneous sensitivity (urticaria and/or angioedema), and systemic sensitivity (anaphylactoid reaction).⁶ Various terms have been used to describe the hypersensitivity reactions to ASA, including ASA intolerance, ASA idiosyncrasy, pseudoallergic reactions, and ASA sensitivity.⁷ The prevalence of ASA sensitivity in cardiovascular patients is not well known. Besides substitution with an alternative class of antiplatelet agents such as thienopyridines, ASA desensitization is an option for ASA-allergic patients who require long-term therapy for cardiovascular diseases.⁷

In this article, we review various hypersensitivity reactions to ASA and discuss desensitization protocols to allow ASA therapy in ASA-sensitive cardiovascular patients.

	Adverse Reactions to ASA

 
ASA-Exacerbated Respiratory Disease
ASA-exacerbated respiratory disease (AERD) is a triad of asthma, ASA sensitivity, and rhinitis/nasal polyps. Patients with AERD have aggressive mucosal inflammation and suffer . . . [Full Text of this Article]

Related Article:

Circulation 2004 110: 1. [Extract] [Full Text]

This article has been cited by other articles:

				Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]

				C. Patrono, L. A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med., December 1, 2005; 353(22): 2373 - 2383. [Full Text] [PDF]

				D. J Fox, T. P Gray, and F. Fath-Ordoubadi Myocardial infarction after aspirin treatment J R Soc Med, January 1, 2005; 98(1): 21 - 23. [Full Text] [PDF]

				R. R. Gollapudi, P. S. Teirstein, D. D. Stevenson, and R. A. Simon Aspirin Sensitivity: Implications for Patients With Coronary Artery Disease JAMA, December 22, 2004; 292(24): 3017 - 3023. [Abstract] [Full Text] [PDF]

				M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]